Interferon signaling has been described as a potent driver of PD-L1 expression in carcinomas31, and peripheral application of IFN-β represents one of the first effective disease modifying therapies (DMT) approved for the treatment of MS. This evidence concerns the gene CD274 and myeloid sarcoma.